Literature DB >> 6378356

Experience with flutamide in patients with advanced prostatic cancer without prior endocrine therapy.

P C Sogani, M R Vagaiwala, W F Whitmore.   

Abstract

Seventy-two patients with advanced prostatic carcinoma without previous endocrine therapy were treated with an oral nonsteroidal antiandrogen, flutamide. Sixty-three patients (87.5%) had a favorable response, and 9 patients showed no response. Flutamide appears to be a safe antiandrogen, usually effective in the management of patients with advanced prostatic cancer who have had no prior endocrine therapy.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6378356     DOI： 10.1002/1097-0142(1984)54:4<744::aid-cncr2820540426>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Clinical pharmacokinetics of the antiandrogens and their efficacy in prostate cancer.

Authors:  C Mahler; J Verhelst; L Denis
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

Review 2.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 3.  The effects of testosterone on the cavernous tissue and erectile function.

Authors:  R Shabsigh
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 4.  Antiandrogens in prostate cancer.

Authors:  P Reid; P Kantoff; W Oh
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

5.  Flutamide-induced toxic hepatitis. Potential utility of ursodeoxycholic acid administration in toxic hepatitis.

Authors:  C Cicognani; M Malavolti; A M Morselli-Labate; C Sama; L Barbara
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

Review 6.  Concept and viability of androgen annihilation for advanced prostate cancer.

Authors:  James L Mohler
Journal:  Cancer       Date:  2014-04-25       Impact factor: 6.860

Review 7.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

8.  Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.

Authors:  R S Witte; B Y Yeap; D L Trump
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

9.  The pharmacokinetics of flutamide and its major metabolites after a single oral dose and during chronic treatment.

Authors:  M Schulz; A Schmoldt; F Donn; H Becker
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.